Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM).

Mendoza TR, Williams LA, Keating KN, Siegel J, Elbi C, Nowak AK, Hassan R, Cuffel B, Cleeland CS.

J Patient Rep Outcomes. 2019 Jun 17;3(1):34. doi: 10.1186/s41687-019-0122-5.

2.

Anetumab ravtansine inhibits tumor growth and shows additive effect in combination with targeted agents and chemotherapy in mesothelin-expressing human ovarian cancer models.

Quanz M, Hagemann UB, Zitzmann-Kolbe S, Stelte-Ludwig B, Golfier S, Elbi C, Mumberg D, Ziegelbauer K, Schatz CA.

Oncotarget. 2018 Sep 25;9(75):34103-34121. doi: 10.18632/oncotarget.26135. eCollection 2018 Sep 25.

3.

Turkish Ministry of Health, 2nd Turkish Medical General Assembly Clinical Oncology Study Group Report.

Özmen V, Dağoğlu N, Dede İ, Akçakaya A, Kerem M, Göksel F, Özgür E, Başkan E, Yaylacı M, Ceydeli A, Baykara M, Kızıltan HŞ, Kömürcü Ş, Gümüş M, Türk HM, Demirhan R, Akgün A, Kadoglou N, Yatman E, Elbi CC, Güleç S, Soran A, Özet A, Keleştimur F.

J Breast Health. 2016 Jan 1;12(1):9-17. doi: 10.5152/tjbh.2015.2869. eCollection 2016 Jan.

4.

Treatment with the PARP inhibitor, niraparib, sensitizes colorectal cancer cell lines to irinotecan regardless of MSI/MSS status.

Genther Williams SM, Kuznicki AM, Andrade P, Dolinski BM, Elbi C, O'Hagan RC, Toniatti C.

Cancer Cell Int. 2015 Feb 4;15(1):14. doi: 10.1186/s12935-015-0162-8. eCollection 2015.

5.

Reducing the multidimensionality of high-content screening into versatile powerful descriptors.

Gorenstein J, Zack B, Marszalek JR, Bagchi A, Subramaniam S, Carroll P, Elbi C.

Biotechniques. 2010 Sep;49(3):663-5. doi: 10.2144/000113492.

6.

Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia.

Tammam J, Ware C, Efferson C, O'Neil J, Rao S, Qu X, Gorenstein J, Angagaw M, Kim H, Kenific C, Kunii K, Leach KJ, Nikov G, Zhao J, Dai X, Hardwick J, Scott M, Winter C, Bristow L, Elbi C, Reilly JF, Look T, Draetta G, Van der Ploeg L, Kohl NE, Strack PR, Majumder PK.

Br J Pharmacol. 2009 Nov;158(5):1183-95. doi: 10.1111/j.1476-5381.2009.00389.x. Epub 2009 Sep 23.

7.

Chromatin remodeling complexes interact dynamically with a glucocorticoid receptor-regulated promoter.

Johnson TA, Elbi C, Parekh BS, Hager GL, John S.

Mol Biol Cell. 2008 Aug;19(8):3308-22. doi: 10.1091/mbc.E08-02-0123. Epub 2008 May 28.

8.

FGFR2-amplified gastric cancer cell lines require FGFR2 and Erbb3 signaling for growth and survival.

Kunii K, Davis L, Gorenstein J, Hatch H, Yashiro M, Di Bacco A, Elbi C, Lutterbach B.

Cancer Res. 2008 Apr 1;68(7):2340-8. doi: 10.1158/0008-5472.CAN-07-5229. Erratum in: Cancer Res. 2008 May 1;68(9):3550.

9.

Induction of apoptosis in human prostate cancer cells by insulin-like growth factor binding protein-3 does not require binding to retinoid X receptor-alpha.

Zappala G, Elbi C, Edwards J, Gorenstein J, Rechler MM, Bhattacharyya N.

Endocrinology. 2008 Apr;149(4):1802-12. Epub 2007 Dec 27.

10.

The ligand binding domain controls glucocorticoid receptor dynamics independent of ligand release.

Meijsing SH, Elbi C, Luecke HF, Hager GL, Yamamoto KR.

Mol Cell Biol. 2007 Apr;27(7):2442-51. Epub 2007 Jan 29.

11.

Ligand-specific dynamics of the androgen receptor at its response element in living cells.

Klokk TI, Kurys P, Elbi C, Nagaich AK, Hendarwanto A, Slagsvold T, Chang CY, Hager GL, Saatcioglu F.

Mol Cell Biol. 2007 Mar;27(5):1823-43. Epub 2006 Dec 22.

12.

Nonsecreted insulin-like growth factor binding protein-3 (IGFBP-3) can induce apoptosis in human prostate cancer cells by IGF-independent mechanisms without being concentrated in the nucleus.

Bhattacharyya N, Pechhold K, Shahjee H, Zappala G, Elbi C, Raaka B, Wiench M, Hong J, Rechler MM.

J Biol Chem. 2006 Aug 25;281(34):24588-601. Epub 2006 Jun 22.

13.

Chromatin dynamics and the evolution of alternate promoter states.

Hager GL, Elbi C, Johnson TA, Voss T, Nagaich AK, Schiltz RL, Qiu Y, John S.

Chromosome Res. 2006;14(1):107-16. Review.

PMID:
16506100
14.

Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer.

Korkmaz CG, Korkmaz KS, Kurys P, Elbi C, Wang L, Klokk TI, Hammarstrom C, Troen G, Svindland A, Hager GL, Saatcioglu F.

Oncogene. 2005 Jul 21;24(31):4934-45.

PMID:
15897894
15.

Ligand-specific dynamics of the progesterone receptor in living cells and during chromatin remodeling in vitro.

Rayasam GV, Elbi C, Walker DA, Wolford R, Fletcher TM, Edwards DP, Hager GL.

Mol Cell Biol. 2005 Mar;25(6):2406-18.

16.

Subnuclear trafficking and gene targeting by steroid receptors.

Nagaich AK, Rayasam GV, Martinez ED, Becker M, Qiu Y, Johnson TA, Elbi C, Fletcher TM, John S, Hager GL.

Ann N Y Acad Sci. 2004 Jun;1024:213-20. Review.

PMID:
15265783
17.

Global nature of dynamic protein-chromatin interactions in vivo: three-dimensional genome scanning and dynamic interaction networks of chromatin proteins.

Phair RD, Scaffidi P, Elbi C, Vecerová J, Dey A, Ozato K, Brown DT, Hager G, Bustin M, Misteli T.

Mol Cell Biol. 2004 Jul;24(14):6393-402.

18.

A novel in situ assay for the identification and characterization of soluble nuclear mobility factors.

Elbi C, Walker DA, Lewis M, Romero G, Sullivan WP, Toft DO, Hager GL, DeFranco DB.

Sci STKE. 2004 Jun 22;2004(238):pl10.

PMID:
15213337
19.

Independent actions on cyclin-dependent kinases and aryl hydrocarbon receptor mediate the antiproliferative effects of indirubins.

Knockaert M, Blondel M, Bach S, Leost M, Elbi C, Hager GL, Nagy SR, Han D, Denison M, Ffrench M, Ryan XP, Magiatis P, Polychronopoulos P, Greengard P, Skaltsounis L, Meijer L.

Oncogene. 2004 May 27;23(25):4400-12.

PMID:
15077192
20.

Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer.

Xi Z, Klokk TI, Korkmaz K, Kurys P, Elbi C, Risberg B, Danielsen H, Loda M, Saatcioglu F.

Cancer Res. 2004 Apr 1;64(7):2365-70.

21.

Molecular chaperones function as steroid receptor nuclear mobility factors.

Elbi C, Walker DA, Romero G, Sullivan WP, Toft DO, Hager GL, DeFranco DB.

Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2876-81. Epub 2004 Feb 20.

22.

Phosphorylation of p53 at serine 37 is important for transcriptional activity and regulation in response to DNA damage.

Dohoney KM, Guillerm C, Whiteford C, Elbi C, Lambert PF, Hager GL, Brady JN.

Oncogene. 2004 Jan 8;23(1):49-57.

PMID:
14712210
23.
24.

Molecular cloning and characterization of STAMP1, a highly prostate-specific six transmembrane protein that is overexpressed in prostate cancer.

Korkmaz KS, Elbi C, Korkmaz CG, Loda M, Hager GL, Saatcioglu F.

J Biol Chem. 2002 Sep 27;277(39):36689-96. Epub 2002 Jul 2.

25.

Recruitment of dioxin receptor to active transcription sites.

Elbi C, Misteli T, Hager GL.

Mol Biol Cell. 2002 Jun;13(6):2001-15.

26.

Protein dynamics in the nuclear compartment.

Hager GL, Elbi C, Becker M.

Curr Opin Genet Dev. 2002 Apr;12(2):137-41. Review.

PMID:
11893485
27.

Trafficking of nuclear receptors in living cells.

Hager GL, Lim CS, Elbi C, Baumann CT.

J Steroid Biochem Mol Biol. 2000 Nov 30;74(5):249-54. Review.

PMID:
11162932
28.

Inducer-dependent transcriptional activation of the P4501A2 gene in vivo and in isolated hepatocytes.

Pasco DS, Boyum KW, Elbi C, Siu CS, Fagan JB.

J Biol Chem. 1993 Jan 15;268(2):1053-7.

Supplemental Content

Support Center